Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

NCT02591784 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Esophageal

Interventions

DRUG: Nimotuzumab
RADIATION: Radiotherapy

Sponsor

Biotech Pharmaceutical Co., Ltd.